PHARMACOTHERAPY FOR ATRIAL FIBRILLATION: CURRENT POSSIBILITIES AND PROSPECTS

Download full text PDF
Issue: 
2
Year: 
2017

Professor S. Kanosrsky, MD; Yu. Kovalenko, Candidate of Medical Sciences Kuban State Medical University, Krasnodar

The paper presents main areas of pharmacotherapy for atrial fibrillation (AF), such as to reduce the frequency of ventricular contractions and to maintain sinus rhythm. It briefly characterizes the efficacy and safety of antiarrhythmic drugs used to maintain sinus rhythm in patients with AF.
Keywords: 
cardiology
atrial fibrillation
antiarrhythmic drugs
control of the frequency of ventricular contractions
control of sinus rhythm

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS // Eur. Heart J. – 2016; 37: 2893–962.
  2. Benjamin E., Blaha M., Chiuve S. et al. Heart Disease and Stroke Statistics–2017 Update: A Report From the American Heart Association // Circulation. – 2017; Jan 25. [Epub ahead of print].
  3. Kanorskij S.G. Sovremennaja medikamentoznaja terapija fibrilljatsii predserdij: vybor taktiki, antiaritmicheskih preparatov i shem lechenija // Kardiologija. – 2012; 9: 58–63.
  4. Kanorskij S.G. Antiaritmicheskaja terapija u bol'nyh s paroksizmal'noj i persistirujuschej formami fibrilljatsii predserdij: opredelenie dostizhimoj tseli i otsenka imejuschihsja sredstv // Kardiologija. – 2014; 2: 70–4.
  5. Kanorskij S.G. Lechenie bol'nyh s fibrilljatsiej predserdij: poisk optimal'nyh reshenij // Kardiologija. – 2016; 8: 46–53.
  6. Nguyen T., Jolly U., Sidhu K. et al. Atrial fibrillation management: evaluating rate vs rhythm control // Expert Rev. Cardiovasc. Ther. – 2016; 14: 713–24.
  7. Chatterjee S., Sardar P., Lichstein E. et al. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis // Pacing Clin. Electrophysiol. – 2013; 36: 122–33.
  8. Ionescu-Ittu R., Abrahamowicz M., Jackevicius C. et al. Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation // Arch. Intern. Med. – 2012; 172: 997–1004.
  9. Halsey C., Chugh A. Rate Versus Rhythm Control for Atrial Fibrillation // Heart Fail. Clin. – 2016; 12: 193–203.
  10. Corley S., Epstein A., DiMarco J. et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study // Circulation. – 2004; 109: 1509–13.
  11. Lip G., Laroche C., Ioachim P. et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry) // Eur. Heart J. – 2014; 35: 3365–76.
  12. January C., Wann L., Alpert J. et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society // Circulation. – 2014; 130: e199–267.
  13. Kotecha D., Holmes J., Krum H. et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis // Lancet. – 2014; 384: 2235–43.
  14. Ponikowski P., Voors A., Anker S. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC // Eur. Heart J. – 2016; 37: 2129–200.
  15. Ulimoen S., Enger S., Pripp A. et al. Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation // Eur. Heart J. – 2014; 35: 517–24.
  16. Ziff O., Lane D., Samra M. et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data // BMJ. – 2015; 351: h4451.
  17. Van Gelder I., Wyse D., Chandler M. et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies // Europace. – 2006; 8: 935–42.
  18. Van Gelder I., Groenveld H., Crijns H. et al. Lenient versus strict rate control in patients with atrial fibrillation // N. Engl. J. Med. – 2010; 362: 1363–73.
  19. Steinberg B., Kim S., Thomas L. et al. Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF) // J. Am. Heart Assoc. – 2015; 4: e002031.
  20. Van Gelder I., Rienstra M., Crijns H. et al. Rate control in atrial fibrillation // Lancet. – 2016; 388: 818–28.
  21. Piccini J., Fauchier L. Rhythm control in atrial fibrillation // Lancet. – 2016; 388: 829–40.
  22. Lafuente-Lafuente C., Valembois L., Bergmann J. et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation // Cochrane Database Syst. Rev. – 2015; 3: CD005049.
  23. Zimetbaum P., Waks J. Antiarrhythmic Drug Therapy for Rhythm Control in Atrial Fibrillation // J. Cardiovasc. Pharmacol. Ther. – 2017; 22: 3–19.
  24. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators // N. Engl. J. Med. – 1989; 321: 406–12.
  25. Hayward C., Patel H., Patel K. et al. The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998–2014 // Eur. Heart J. Cardiovasc. Pharmacother. – 2016; 2: 90–4.
  26. Roy D., Talajic M., Dorian P. et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators // N. Engl. J. Med. – 2000; 342: 913–20.
  27. Singh B., Singh S., Reda D. et al. Amiodarone versus sotalol for atrial fibrillation // N. Engl. J. Med. – 2005; 352: 1861–72.
  28. Bardy G., Lee K., Mark D. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure // N. Engl. J. Med. – 2005; 352: 225–37.
  29. Danzi S., Klein I. Amiodarone-induced thyroid dysfunction // J. Intensive Care Med. – 2015; 30: 179–85.
  30. Schweizer P., Becker R., Katus H. et al. Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation // Drug Des. Devel. Ther. – 2011; 5: 27–39.
  31. Hohnloser S., Crijns H., van Eickels M. et al. Effect of dronedarone on cardiovascular events in atrial fibrillation // N. Engl. J. Med. – 2009; 360: 668–78.
  32. Connolly S., Camm A., Halperin J. et al. Dronedarone in high-risk permanent atrial fibrillation // N. Engl. J. Med. – 2011; 365: 2268–76.
  33. Køber L., Torp-Pedersen C., McMurray J. et al. Increased mortality after dronedarone therapy for severe heart failure // N. Engl. J. Med. – 2008; 358: 2678–87.
  34. De Vos C., Breithardt G., Camm A. et al. Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythm-control therapy // Am. Heart J. – 2012; 163: 887–93.
  35. Aguilar M., Xiong F., Qi X. et al. Potassium Channel Blockade Enhances Atrial Fibrillation-Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade // Circulation. – 2015; 132: 2203–11.
  36. Capucci A., Piangerelli L., Ricciotti J. et al. Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation // Europace. – 2016; 18: 1698–704.
  37. Ha A., Wijeysundera H., Birnie D. et al. Real-world outcomes, complications, and cost of catheter-based ablation for atrial fibrillation: an update // Curr. Opin. Cardiol. – 2017; 32: 47–52.
  38. Link M., Haïssaguerre M., Natale A. Ablation of Atrial Fibrillation: Patient Selection, Periprocedural Anticoagulation, Techniques, and Preventive Measures After Ablation // Circulation. – 2016; 134: 339–52.
  39. Steinberg B., Hellkamp A., Lokhnygina Y. et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial // Eur. Heart J. – 2015; 36: 288–96.
  40. Al-Khatib S., Thomas L., Wallentin L. et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial // Eur. Heart J. – 2013; 34: 2464–71.
  41. Link M., Giugliano R., Ruff C. et al. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) // Circ. Arrhythm. Electrophysiol. – 2017; 10: e004267.
  42. Zimetbaum P., Waks J., Ellis E. et al. Role of atrial fibrillation burden in assessing thromboembolic risk // Circ. Arrhythm. Electrophysiol. – 2014; 7: 1223–9.
  43. Healey J., Connolly S., Gold M. et al. Subclinical atrial fibrillation and the risk of stroke // N. Engl. J. Med. – 2012; 366: 120–9.
  44. Passman R., Leong-Sit P., Andrei A. et al. Targeted Anticoagulation for Atrial Fibrillation Guided by Continuous Rhythm Assessment With an Insertable Cardiac Monitor: The Rhythm Evaluation for Anticoagulation With Continuous Monitoring (REACT.COM) Pilot Study // J. Cardiovasc. Electrophysiol. – 2016; 27: 264–70.